Microbiome upstart Vedanta gets an extra $18.5M in the bank, wrapping up $45.5 series C round

Apart from a few pitfalls, such as Seres Therapeutics’ seminal effort into developing a “crapsule” — the emerging field aiming to harness insights gained from gut microbiota to develop drugs has attracted a bucket of biobucks and even inspired the takeover of a key player, Rebiotix. The enthusiasm persists, with upstart Vedanta Biosciences attracting an additional $18.5 million in its series C round.